Physician profile
Ivan D Flint
NPI 1962484485
$413.61
in general payments reported to CMS, 2019-2025
11 companies · $96.01 in 2025
The $96.01 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.65 · 2020: $21.37 · 2021: $30.04 · 2022: $81.84 · 2023: $20.04 · 2024: $116 · 2025: $96.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.82 | 2024 | Arazlo, Cabtreo, Altreno |
| Pfizer INC. | $76.66 | 2019-2023 | |
| Abbvie INC. | $50.07 | 2020-2025 | |
| Botanix Sb INC | $39.08 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $37.55 | 2019-2022 | |
| Leo Pharma INC. | $26.12 | 2025 | Adbry |
| Amgen INC. | $25.51 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.70 | 2021 | |
| Lilly USA, LLC | $14.84 | 2024 | Taltz |
| Ucb, INC. | $14.45 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Flint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.